237 related articles for article (PubMed ID: 20147978)
1. Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: long-term follow-up.
Shimoni A; Hardan I; Shem-Tov N; Yerushalmi R; Nagler A
Leukemia; 2010 May; 24(5):1050-2. PubMed ID: 20147978
[No Abstract] [Full Text] [Related]
2. Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity.
Shimoni A; Hardan I; Shem-Tov N; Yeshurun M; Yerushalmi R; Avigdor A; Ben-Bassat I; Nagler A
Leukemia; 2006 Feb; 20(2):322-8. PubMed ID: 16307018
[TBL] [Abstract][Full Text] [Related]
3. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.
Valcárcel D; Martino R; Caballero D; Martin J; Ferra C; Nieto JB; Sampol A; Bernal MT; Piñana JL; Vazquez L; Ribera JM; Besalduch J; Moraleda JM; Carrera D; Brunet MS; Perez-Simón JA; Sierra J
J Clin Oncol; 2008 Feb; 26(4):577-84. PubMed ID: 18086801
[TBL] [Abstract][Full Text] [Related]
4. Treatment of AML and MDS relapsing after reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation.
Oran B; Giralt S; Couriel D; Hosing C; Shpall EJ; de Meis E; Khouri IF; Qazilbash M; Anderlini P; Kebriaei P; Popat U; Carrasco-Yalan A; Champlin RE; de Lima M
Leukemia; 2007 Dec; 21(12):2540-4. PubMed ID: 17611563
[No Abstract] [Full Text] [Related]
5. Single-unit cord blood transplantation after granulocyte colony-stimulating factor-combined myeloablative conditioning for myeloid malignancies not in remission.
Konuma T; Kato S; Ooi J; Oiwa-Monna M; Ebihara Y; Mochizuki S; Yuji K; Ohno N; Kawamata T; Jo N; Yokoyama K; Uchimaru K; Asano S; Tojo A; Takahashi S
Biol Blood Marrow Transplant; 2014 Mar; 20(3):396-401. PubMed ID: 24333750
[TBL] [Abstract][Full Text] [Related]
6. The Art of Transplantation: Conditioning Intensity for Allogeneic Hematopoietic Stem Cell Transplantation.
Ragon BK
Biol Blood Marrow Transplant; 2019 Mar; 25(3):e71-e72. PubMed ID: 30562588
[TBL] [Abstract][Full Text] [Related]
7. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.
Kröger N; Bornhäuser M; Ehninger G; Schwerdtfeger R; Biersack H; Sayer HG; Wandt H; Schäfer-Eckardt K; Beyer J; Kiehl M; Zander AR;
Ann Hematol; 2003 Jun; 82(6):336-42. PubMed ID: 12728337
[TBL] [Abstract][Full Text] [Related]
8. Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis.
Scott BL; Sandmaier BM; Storer B; Maris MB; Sorror ML; Maloney DG; Chauncey TR; Storb R; Deeg HJ
Leukemia; 2006 Jan; 20(1):128-35. PubMed ID: 16270037
[TBL] [Abstract][Full Text] [Related]
9. Impact of pre-transplant serum ferritin on outcomes of patients with myelodysplastic syndromes or secondary acute myeloid leukaemia receiving reduced intensity conditioning allogeneic haematopoietic stem cell transplantation.
Lim ZY; Fiaccadori V; Gandhi S; Hayden J; Kenyon M; Ireland R; Marsh J; Ho AY; Mufti GJ; Pagliuca A
Leuk Res; 2010 Jun; 34(6):723-7. PubMed ID: 19944463
[TBL] [Abstract][Full Text] [Related]
10. Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in myelodysplastic syndromes and acute myelogenous leukemia.
Valcárcel D; Martino R
Curr Opin Oncol; 2007 Nov; 19(6):660-6. PubMed ID: 17906468
[TBL] [Abstract][Full Text] [Related]
11. Long-term remissions in patients with myelodysplastic syndrome and secondary acute myelogenous leukemia undergoing allogeneic transplantation following a reduced intensity conditioning regimen of 550 cGy total body irradiation and cyclophosphamide.
Hallemeier CL; Girgis MD; Blum WG; Brown RA; Khoury HJ; Devine SM; Vij R; Lin HS; DiPersio JF; Adkins DR
Biol Blood Marrow Transplant; 2006 Jul; 12(7):749-57. PubMed ID: 16785064
[TBL] [Abstract][Full Text] [Related]
12. Allogeneic hematopoietic stem cell transplantation (HSCT) for high-risk acute myeloid leukemia (AML)/myelodysplastic syndrome (MDS): how can we improve outcomes in the near future?
Phillips GL
Leuk Res; 2012 Dec; 36(12):1490-5. PubMed ID: 22954609
[TBL] [Abstract][Full Text] [Related]
13. Full-intensity and reduced-intensity allogeneic stem cell transplantation in AML.
Craddock CF
Bone Marrow Transplant; 2008 Mar; 41(5):415-23. PubMed ID: 18209726
[TBL] [Abstract][Full Text] [Related]
14. [Mini-transplant for acute myeloblastic leukemia and myelodysplastic syndrome].
Kanda Y
Nihon Rinsho; 2003 Sep; 61(9):1565-72. PubMed ID: 14515725
[TBL] [Abstract][Full Text] [Related]
15. Impact of disease burden at time of allogeneic stem cell transplantation in adults with acute myeloid leukemia and myelodysplastic syndromes.
Kebriaei P; Kline J; Stock W; Kasza K; Le Beau MM; Larson RA; van Besien K
Bone Marrow Transplant; 2005 May; 35(10):965-70. PubMed ID: 15806131
[TBL] [Abstract][Full Text] [Related]
16. Time to engraftment following allogeneic stem cell transplantation is significantly longer in patients with myelodysplastic syndrome than with acute myeloid leukemia.
Bitan M; Or R; Shapira MY; Resnick IB; Gesundheit B; Ackerstein A; Samuel S; Elad S; Slavin S
Bone Marrow Transplant; 2008 Jan; 41(1):69-78. PubMed ID: 17994125
[TBL] [Abstract][Full Text] [Related]
17. Upfront allogeneic blood stem cell transplantation for patients with high-risk myelodysplastic syndrome or secondary acute myeloid leukemia using a FLAMSA-based high-dose sequential conditioning regimen.
Saure C; Schroeder T; Zohren F; Groten A; Bruns I; Czibere A; Galonska L; Kondakci M; Weigelt C; Fenk R; Germing U; Haas R; Kobbe G
Biol Blood Marrow Transplant; 2012 Mar; 18(3):466-72. PubMed ID: 21963618
[TBL] [Abstract][Full Text] [Related]
18. Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome.
Schmid C; Schleuning M; Ledderose G; Tischer J; Kolb HJ
J Clin Oncol; 2005 Aug; 23(24):5675-87. PubMed ID: 16110027
[TBL] [Abstract][Full Text] [Related]
19. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D
Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
[TBL] [Abstract][Full Text] [Related]
20. Predictors of outcome following myeloablative allo-SCT for therapy-related myelodysplastic syndrome and AML.
Nevill TJ; Hogge DE; Toze CL; Nantel SH; Power MM; Abou Mourad YR; Song KW; Lavoie JC; Forrest DL; Barnett MJ; Shepherd JD; Nitta JY; Wong S; Sutherland HJ; Smith CA
Bone Marrow Transplant; 2008 Nov; 42(10):659-66. PubMed ID: 18679372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
